Inference proceeds from ingredients chosen by the analyst and data. To validate any inferences drawn it is essential that the inputs chosen be deemed appropriate for the data. In the Bayesian context these inputs consist of both the sampling model and the prior. There are thus two possibilities for failure: the data may not have arisen from the sampling model, or the prior may place most of its mass on parameter values that are not feasible in light of the data (referred to here as prior-data conflict). Failure of the sampling model can only be fixed by modifying the model, while prior-data conflict can be overcome if sufficient data is available. We examine how to assess whether or not a prior-data conflict exists, and how to assess when its effects can be ignored for inferences. The concept of prior-data conflict is seen to lead to a partial characterization of what is meant by a noninformative prior or a noninformative sequence of priors.
There was a statistically significant difference in the values of the quantitative shear wave elastography parameters of benign and malignant solid breast masses. By adding shear wave elastography parameters to BI-RADS category 4a masses, we found that about 90% of them could be correctly downgraded to BI-RADS category 3, thereby avoiding biopsy. Elasticity ratio (cutoff, 3.56) appeared to be the most discriminatory parameter.
Cystic RCCs exhibit slow indolent growth, if any, and show no significant metastatic or recurrence potential, with excellent clinical outcomes. We raise the need for revisiting current imaging protocols that may involve frequent pre-and posttreatment imaging in cystic RCCs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.